Condition

Multiple Myeloma (MM) clinical trials and research

• 25Clinical trials
• 14Countries

Newest Multiple Myeloma (MM) clinical trials

All recruiting trials (25)

• Cognitive changes after BCMA CAR-T in multiple myeloma

  This study tests whether cognitive function changes over time in adults with relapsed or refractory multiple myeloma who receive BCMA CAR-T therapy.

  Recruiting Wake Forest University Health Sciences · Charlotte, North Carolina · NCT07740317

• GPRC5D-targeted PET/CT imaging in plasma cell disorders

  This study tests a new GPRC5D-targeted PET/CT imaging method in adults with plasma cell disorders to see if it detects disease better or differently than standard imaging.

  Recruiting Phase 1 Peking University First Hospital · Beijing, Beijing Municipality · NCT07660939

• Gustabor: Tailored AI Nutrition for Taste Changes During Cancer Therapy

  This trial tests whether personalized, AI-assisted dietary advice helps people with taste changes from cancer treatment compare to general dietary guidance.

  Recruiting at 2 sites Wuerzburg University Hospital · Augsburg, Bavaria and 5 other locations · NCT07649681

• Personalising Myeloma Treatment Based on Initial Response and Fitness

  This trial tests whether adjusting treatment after six months of the standard DRd therapy, based on a patient’s response and fitness, can improve outcomes for older, transplant-ineligible patients with myeloma.

  Recruiting Phase 3 University of Leeds · Bristol and 4 other locations · NCT07649525

• Elranatamab given as outpatient in relapsed or refractory multiple myeloma

  This study tests a bispecific antibody called elranatamab, given in an outpatient setting to adults with relapsed or refractory multiple myeloma who have had prior therapies.

  Recruiting at 6 sites Phase 2 SCRI Development Innovations, LLC · Denver, Colorado and 5 other locations · NCT07637578

• CM336 with Isatuximab for Newly Diagnosed Myeloma with Kidney Impairment

  This study tests a CM336 and isatuximab regimen in adults with newly diagnosed multiple myeloma and kidney trouble to see if it helps.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07585760

• Beta-hydroxybutyrate to boost immunotherapy in multiple myeloma

  This study will test whether raising blood beta-hydroxybutyrate with a ketogenic diet or oral ketone supplements can safely improve responses to CAR‑T or BCMA‑directed bispecific therapy in adults with multiple myeloma.

  Recruiting Universitätsklinikum Hamburg-Eppendorf · Hamburg, Free and Hanseatic City of Hamburg · NCT07564219

• 6-month individualized hybrid adapted physical activity program for people with multiple myeloma

  This trial will test whether a 6-month individualized program of adapted physical activity, mixing remote home sessions and in-person hospital sessions, can improve quality of life for people over 60 treated for multiple myeloma who are not eligible for transplant.

  Recruiting at 2 sites Centre Hospitalier Metropole Savoie · Annecy and 1 other locations · NCT07547007

• HLX15-SC vs Darzalex FASPRO in transplant-ineligible, newly diagnosed multiple myeloma

  This study tests whether HLX15 given under the skin works similarly to Daratumumab FASPRO when added to lenalidomide and dexamethasone in adults with newly diagnosed multiple myeloma who can’t have transplant.

  Recruiting at 79 sites Phase 1 Shanghai Henlius Biotech · Springdale, Arkansas and 83 other locations · NCT07477587

• QI-019A CAR-T therapy for relapsed/refractory multiple myeloma

  A single-arm study tests whether the QI-019A CAR-T therapy is safe and shows signs of activity in adults with relapsed or refractory multiple myeloma.

  Recruiting Early Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07429721

• Controlled breathing added to exercise for people with multiple myeloma

  This study tests whether adding a home-based controlled breathing program to a therapeutic exercise plan helps improve heart and lung health in adults with multiple myeloma.

  Recruiting Universidad Complutense de Madrid · Madrid · NCT07376733

• Monitoring CAR‑BCMA immune cells in multiple myeloma

  This project will test whether tracking CAR‑BCMA cells and related immune markers in blood and bone marrow can help predict which multiple myeloma patients respond to CAR‑T therapy.

  Recruiting Poitiers University Hospital · Poitiers · NCT07342179

• Adding SCTC21C to standard bortezomib–lenalidomide–dexamethasone (VRd) for newly diagnosed multiple myeloma patients not eligible for transplant.

  This trial will test whether adding the experimental drug SCTC21C to the standard bortezomib–lenalidomide–dexamethasone (VRd) regimen helps people with newly diagnosed multiple myeloma who are not eligible for transplant live longer without disease progression and reach deeper remissions.

  Recruiting Phase 3 Sinocelltech Ltd. · Beijing, Beijing Municipality · NCT07297329

• Cemsidomide plus elranatamab for relapsed or refractory multiple myeloma

  This will try giving cemsidomide pills together with elranatamab injections to see if the combination is safe and helps people with relapsed or refractory multiple myeloma.

  Recruiting at 12 sites Phase 1 C4 Therapeutics, Inc. · Gilbert, Arizona and 18 other locations · NCT07280013

• A 16-week lifestyle program for people with multiple myeloma

  We’re testing whether a 16-week eating and exercise plan can improve physical function, quality of life, and aging-related blood markers in adults with multiple myeloma.

  Recruiting at 2 sites Medical College of Wisconsin · Maywood, Illinois and 1 other locations · NCT07236502

• Multi-omics profiling to predict progression from MGUS and smoldering myeloma to symptomatic multiple myeloma

  This project will try to see if combined genomic, immune, and oral microbiome tests can predict which people with MGUS or smoldering myeloma will progress to symptomatic multiple myeloma.

  Recruiting Azienda USL Reggio Emilia - IRCCS · Bologna and 3 other locations · NCT07214324

• Daratumumab combined with teclistamab or talquetamab for frail adults with newly diagnosed multiple myeloma

  This study will test whether adding teclistamab or talquetamab to daratumumab helps frail adults newly diagnosed with multiple myeloma remain progression-free at 18 months.

  Recruiting at 6 sites Phase 2 European Myeloma Network B.V. · Ascoli Piceno and 28 other locations · NCT07107529

• OriV508 injection for relapsed or refractory multiple myeloma and aggressive B‑cell lymphoma

  We will try OriV508, an in‑body lentiviral therapy carrying a BCMA/CD19 dual‑target CAR, in adults whose multiple myeloma or aggressive B‑cell lymphoma has returned or not responded to prior treatments.

  Recruiting Early Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07101705

• Metabolically armed BCMA CAR-T (Meta10-BCMA) for relapsed or refractory plasma cell neoplasms

  This treatment tries a metabolically modified BCMA-targeted CAR-T cell therapy for adults with relapsed or refractory multiple myeloma, plasma cell leukemia, or AL amyloidosis who have had at least three prior therapies.

  Recruiting Early Phase 1 Anhui Provincial Hospital · Hefei, Anhui · NCT07085559

• Quality of life and treatment outcomes for relapsed/refractory multiple myeloma with advanced versus conventional immunotherapies.

  This will test whether advanced immuno-oncology treatments lead to different quality of life, safety, and treatment outcomes than conventional immunotherapies in adults with relapsed or refractory multiple myeloma.

  Recruiting Seoul St. Mary's Hospital · Seocho, Seoul · NCT07051850

• What affects quality of life and everyday participation for people with multiple myeloma and their caregivers

  This project will try to identify factors that affect quality of life and everyday participation for adults with multiple myeloma and their primary informal caregivers.

  Recruiting Azienda USL Reggio Emilia - IRCCS · Reggio Emilia, RE · NCT07014865

• Frontline T-cell engager plus daratumumab versus autologous stem cell transplant with MRD-guided intensification for newly diagnosed multiple myeloma

  This trial tests whether a BCMA-directed T-cell engager (elranatamab) combined with daratumumab can replace autologous stem cell transplant and use MRD results to guide later intensification in adults with newly diagnosed multiple myeloma who already completed standard induction therapy.

  Recruiting at 10 sites Phase 2 SCRI Development Innovations, LLC · Birmingham, Alabama and 10 other locations · NCT06974786

• Developing a tool to monitor infections and quality of life in patients with blood cancers and immune issues

  This study is testing a new tool that helps people with blood cancers like CLL or multiple myeloma report infections and track their quality of life to see how it can improve their treatment.

  Recruiting Medical University Innsbruck · Innsbruck, Tyrolia and 4 other locations · NCT06821880

• Using machine learning to predict early recurrence in multiple myeloma patients

  This study is testing if using machine learning can help doctors predict which patients with multiple myeloma are at higher risk for early relapse after treatment.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Meldola, Forlì-Cesena and 3 other locations · NCT06767254

• Testing IDP-121 in patients with certain blood cancers

  This study is testing a new treatment called IDP-121 to see if it can help people with certain blood cancers, like multiple myeloma and lymphoma, feel better and live longer.

  Recruiting at 11 sites Phase 1/2 IDP Discovery Pharma S.L. · Santander, Cantabria and 10 other locations · NCT05908409

Related topics

Quick answers

How many Multiple Myeloma (MM) clinical trials are recruiting right now?

25, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 14 countries. The most sites are in China (7 trials), United States (6 trials), Italy (4 trials), Germany (3 trials), Spain (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 4, Phase 1: 3, Early Phase 1: 3, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →